Recent Posts
- Blocking Cancer-Promoting Protein: Enzyme Inhibitor Takes An Unexpected Approach
- Prevent Periodontitis To Reduce The Risk Of Head And Neck Cancer
- Over Ninety Per Cent Of Pathologists Find Research Rules Too Complex
- New Progenitor Cell in Mice Can Cause Prostate Cancer
- Aggressive Prostate Cancer Linked to Trichomonas (CME/CE)
Random Posts
- CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity In Animal Trial For Multiple Myeloma
- Volcanic Area Of Sicily Has Higher Incidence Of Thyroid Cancer
- Scientists Reveal 'Protector' Gene Behind 50-fold Increase In Number Of Bowel Tumours
- ECCO-ESMO: Experimental Drug Matches Zoledronic Acid in Bone Mets (CME/CE)
- Office Cystoscopy And Transrectal Ultrasound-guided Prostate Biopsies Pose Minimal Risk: Prospective Evaluation Of 921 Procedures
- MRI Often Rejected over Fear, Inconvenience (CME/CE, with audio)
- Scientists Uncover New Potential For Targeted Cancer Treatment
- Robot's Gentle Touch Aids Delicate Cancer Surgery
- The Mysterious Case Of the Missing Fingerprints (CME/CE)
- Metabolomics Used To Identify The Mechanism Of Action Of An Anti-Cancer Drug
Prescription Cancer Drugs
Meda: Onsolis Receives FDA Approval
Posted by: admin in Prescription Cancer Drugs on July 22nd, 2009
The U.S. fda.gov/” rel=”nofollow”>Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Onsolis uses a unique delivery system designed to give rapid and reliable delivery of fentanyl. The product consists of a small dissolvable disc for application of fentanyl to the buccal (inner lining of cheek) membranes. The product is unique and offers an important step to a better pain treatment of cancer patients.
“I’m very pleased that Onsolis has been approved for marketing in the U.S. For Meda in the U.S., we get yet another important product addition. The interest among specialists for this new technology is significant, and we are making preparations for product launch during the fourth quarter of 2009. The registration procedures for Onsolis in other key markets are progressing according to plan”, said Anders Lonner, CEO Meda.
Meda has, in close collaboration with the FDA and Meda’s development partner BioDelivery Sciences Inc, developed the REMS (Risk Evaluation and Mitigation Strategy) program for Onsolis. This REMS program has also been approved by the FDA.
Source
MEDA AB